SCHEMBL23588142

SCHEMBL23588142

C=C(Cc1nc(Cc2ccc(C(F)(F)CCCC)cc2)no1)C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ HDAC6 Q9UBN7 2/20 0.34
▸ TSHR P16473 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ HDAC4 P56524 1/20 0.32
▸ GLA P06280 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ ZAP70 P43403 3/20 0.32
▸ PPARG P37231 1/20 0.32
▸ SRC P12931 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23578363 0.88 KMT2A (0.35) KMT2AMEN1MAPTALDH1A1HDAC6
SCHEMBL23588278 0.85 S1PR1 (0.41) KMT2AMEN1MAPTALDH1A1HDAC6
SCHEMBL23588038 0.84 ALDH1A1 (0.43) KMT2AMEN1MAPTALDH1A1TSHR
SCHEMBL23578048 0.83 HDAC2 (0.43) HDAC6HDAC4
SCHEMBL25299009 0.83 ALDH1A1 (0.45) KMT2AMEN1MAPTALDH1A1
SCHEMBL23588094 0.82 TP53 (0.40) KMT2AMAPTALDH1A1HDAC6TSHR
SCHEMBL23588168 0.81 MAPT (0.40) KMT2AMAPTALDH1A1HDAC6TSHR
SCHEMBL23578251 0.81 MAPT (0.45) MAPTALDH1A1HDAC6TSHR
SCHEMBL23588299 0.78 MAPT (0.39) KMT2AMAPTALDH1A1HDAC6TSHR
SCHEMBL23578148 0.78 PPARG (0.41) KMT2AMAPTALDH1A1TSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115066418-A Carboxy derivatives with anti-inflammatory properties 西特瑞治疗有限公司 2022-09-16 — — CN claimed
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 — — US disclosed
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 — — US disclosed
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 — — US disclosed
EP-4081511-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES Sitryx Therapeutics Limited (GB) 2022-11-02 — — EP disclosed
CN-115066418-A Carboxy derivatives with anti-inflammatory properties 西特瑞治疗有限公司 2022-09-16 — — CN disclosed
WO-2021130492-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2021-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES CPA2, RO60, C5AR1 KMT2A 3125/4885MEN1 4504/4885MAPT 4683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback